The result can be low potassium, or hypokalaemia, in the first days of treatment
Hypoxia not only manifests as the direct effect of insufficient oxygen supply to tissues, but the microenvironmental disturbances it triggers are often accompanied by significant oxidative stress, constituting a core factor exacerbating pathological damage [5]
This also applies to individuals already on a longevity stack or performance protocol including those using peptide therapy, hormone optimisation, or NAD+ infusion who want to assess whether a circadian-regulatory peptide like Epitalon would complement existing interventions without pathway redundancy or signalling interference
Several complementary habits amplify your results
The September 2024 LIFT-AD trial termination after meeting enrollment demonstrates that this approach, despite decades of development, does not slow Alzheimer's cognitive decline in humans